Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 119

1.

Diffusion-weighted MRI in bladder carcinoma: the differentiation between tumor recurrence and benign changes after resection.

Wang HJ, Pui MH, Guo Y, Yang D, Pan BT, Zhou XH.

Abdom Imaging. 2014 Feb;39(1):135-41. doi: 10.1007/s00261-013-0038-0.

PMID:
24072383
2.

Diffusion-weighted magnetic resonance imaging in follow-up of superficial urinary bladder carcinoma after transurethral resection: initial experience.

El-Assmy A, Abou-El-Ghar ME, Refaie HF, Mosbah A, El-Diasty T.

BJU Int. 2012 Dec;110(11 Pt B):E622-7. doi: 10.1111/j.1464-410X.2012.11345.x. Epub 2012 Jul 3.

3.

Multiparametric 3-T MRI for differentiating low-versus high-grade and category T1 versus T2 bladder urothelial carcinoma.

Wang HJ, Pui MH, Guo Y, Li SR, Guan J, Zhang XL, Cai HS.

AJR Am J Roentgenol. 2015 Feb;204(2):330-4. doi: 10.2214/AJR.14.13147.

PMID:
25615755
4.

Initial experience of diffusion-weighted magnetic resonance imaging to assess therapeutic response to induction chemoradiotherapy against muscle-invasive bladder cancer.

Yoshida S, Koga F, Kawakami S, Ishii C, Tanaka H, Numao N, Sakai Y, Saito K, Masuda H, Fujii Y, Kihara K.

Urology. 2010 Feb;75(2):387-91. doi: 10.1016/j.urology.2009.06.111. Epub 2009 Nov 14.

PMID:
19914691
5.

MR imaging of urinary bladder cancer for T-staging: a review and a pictorial essay of diffusion-weighted imaging.

Takeuchi M, Sasaki S, Naiki T, Kawai N, Kohri K, Hara M, Shibamoto Y.

J Magn Reson Imaging. 2013 Dec;38(6):1299-309. doi: 10.1002/jmri.24227. Epub 2013 Nov 21. Review.

PMID:
24265260
6.

Uninterpretable Dynamic Susceptibility Contrast-Enhanced Perfusion MR Images in Patients with Post-Treatment Glioblastomas: Cross-Validation of Alternative Imaging Options.

Heo YJ, Kim HS, Park JE, Choi CG, Kim SJ.

PLoS One. 2015 Aug 21;10(8):e0136380. doi: 10.1371/journal.pone.0136380. eCollection 2015.

8.

Evaluation of locally recurrent pelvic malignancy: performance of T2- and diffusion-weighted MRI with image fusion.

Nishie A, Stolpen AH, Obuchi M, Kuehn DM, Dagit A, Andresen K.

J Magn Reson Imaging. 2008 Sep;28(3):705-13. doi: 10.1002/jmri.21486.

PMID:
18777555
9.

Role of diffusion-weighted imaging as an adjunct to contrast-enhanced breast MRI in evaluating residual breast cancer following neoadjuvant chemotherapy.

Hahn SY, Ko EY, Han BK, Shin JH, Ko ES.

Eur J Radiol. 2014 Feb;83(2):283-8. doi: 10.1016/j.ejrad.2013.10.023. Epub 2013 Nov 20.

PMID:
24315957
10.

Improved diagnostic accuracy with multiparametric magnetic resonance imaging of the breast using dynamic contrast-enhanced magnetic resonance imaging, diffusion-weighted imaging, and 3-dimensional proton magnetic resonance spectroscopic imaging.

Pinker K, Bogner W, Baltzer P, Gruber S, Bickel H, Brueck B, Trattnig S, Weber M, Dubsky P, Bago-Horvath Z, Bartsch R, Helbich TH.

Invest Radiol. 2014 Jun;49(6):421-30. doi: 10.1097/RLI.0000000000000029.

PMID:
24566292
11.

Comparative sensitivities of functional MRI sequences in detection of local recurrence of prostate carcinoma after radical prostatectomy or external-beam radiotherapy.

Roy C, Foudi F, Charton J, Jung M, Lang H, Saussine C, Jacqmin D.

AJR Am J Roentgenol. 2013 Apr;200(4):W361-8. doi: 10.2214/AJR.12.9106.

PMID:
23521479
12.

MRI techniques for prediction of local tumor progression after high-intensity focused ultrasonic ablation of prostate cancer.

Kim CK, Park BK, Lee HM, Kim SS, Kim E.

AJR Am J Roentgenol. 2008 May;190(5):1180-6. doi: 10.2214/AJR.07.2924.

PMID:
18430829
13.

Prostate cancer: role of pretreatment multiparametric 3-T MRI in predicting biochemical recurrence after radical prostatectomy.

Park JJ, Kim CK, Park SY, Park BK, Lee HM, Cho SW.

AJR Am J Roentgenol. 2014 May;202(5):W459-65. doi: 10.2214/AJR.13.11381.

PMID:
24758681
14.

[The actions of diffusion weighted imaging (DWI) and dynamic contrast enhanced MRI in differentiating breast tumors].

Luo Y, Yu J, Chen D, Xu Z, Zeng H.

Sheng Wu Yi Xue Gong Cheng Xue Za Zhi. 2013 Dec;30(6):1219-23. Chinese.

PMID:
24645600
15.

Utility of quantitative MRI metrics for assessment of stage and grade of urothelial carcinoma of the bladder: preliminary results.

Rosenkrantz AB, Haghighi M, Horn J, Naik M, Hardie AD, Somberg MB, Melamed J, Xiao GQ, Huang WC, Taouli B.

AJR Am J Roentgenol. 2013 Dec;201(6):1254-9. doi: 10.2214/AJR.12.10348.

PMID:
24261364
16.

Prostate cancer recurrence after radical prostatectomy: the role of 3-T diffusion imaging in multi-parametric magnetic resonance imaging.

Panebianco V, Barchetti F, Sciarra A, Musio D, Forte V, Gentile V, Tombolini V, Catalano C.

Eur Radiol. 2013 Jun;23(6):1745-52. doi: 10.1007/s00330-013-2768-3. Epub 2013 Feb 2.

PMID:
23377546
17.

Improving bladder cancer imaging using 3-T functional dynamic contrast-enhanced magnetic resonance imaging.

Nguyen HT, Pohar KS, Jia G, Shah ZK, Mortazavi A, Zynger DL, Wei L, Clark D, Yang X, Knopp MV.

Invest Radiol. 2014 Jun;49(6):390-5. doi: 10.1097/RLI.0000000000000022.

18.

Preoperative T staging of urinary bladder cancer: efficacy of stalk detection and diagnostic performance of diffusion-weighted imaging at 3T.

Ohgiya Y, Suyama J, Sai S, Kawahara M, Takeyama N, Ohike N, Sasamori H, Munechika J, Saiki M, Onoda Y, Hirose M, Gokan T.

Magn Reson Med Sci. 2014;13(3):175-81. Epub 2014 Jul 2.

19.

Combined T2-weighted and diffusion-weighted MRI for diagnosis of urinary bladder invasion in patients with prostate carcinoma.

Ren J, Huan Y, Li F, Wang H, Ge Y, Chang Y, Yin H, Sun L.

J Magn Reson Imaging. 2009 Aug;30(2):351-6. doi: 10.1002/jmri.21727.

PMID:
19591203
20.

Conventional and diffusion-weighted MRI features in diagnosis of metastatic lymphadenopathy in bladder cancer.

Wollin DA, Deng FM, Huang WC, Babb JS, Rosenkrantz AB.

Can J Urol. 2014 Oct;21(5):7454-9.

PMID:
25347370
Items per page

Supplemental Content

Write to the Help Desk